The U.S. Food and Drug Administration has its hands full making sure medical AI products are safe, efficacious and trustworthy before they hit the market. The rise of ever-more-innovative iterations of the technology—not least generative AI—is only adding to the burden. 

The Texas Hospital Association said answering the question, which stems from an executive order from Gov. Greg Abbot, will not impact patient care.

Device-based therapies can provide considerable value for heart failure patients when used alongside traditional pharmaceutical treatments. A new HFSA scientific statement outlines the benefits of these devices, urging care teams to implement them into daily practice. 

"We are failing to rescue women after high-risk surgery," one researcher said after reviewing years of Medicare data. 

Despite these incidents, CT continues to be the preferred imaging technology for patients with implantable or wearable medical devices.

Most cardiac devices do not fit young children, making it especially important for growth in pediatric cardiology to continue. The FDA helped fund a contest aimed at identifying new devices that show a ton of potential. 

Johnson & Johnson goes full transparency on AI. 

Among AI’s most watchful stakeholders are healthcare organizations in need of AI talent and AI talent in need of work in healthcare. Both groups need to keep up with the technology in its present as well as future iterations.